These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 39079354)

  • 1. Corrigendum to "Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study" [Schizophr. Res. volume 225 (May 2023) 173-181].
    Millgate E; Smart SE; Pardiñas AF; Kravariti E; Ajnakina O; Kępińska AP; Andreassen OA; Barnes TRE; Berardi D; Crespo-Facorro B; D'Andrea G; Demjaha A; Di Forti M; Doody GA; Üçok A; Kassoumeri L; Ferchiou A; Guidi L; Joyce EM; Lastrina O; Melle I; Pignon B; Richard JR; Simonsen C; Szöke A; Tarricone I; Tortelli A; Vázquez-Bourgon J; Murray RM; Walters JTR; MacCabe JH;
    Schizophr Res; 2024 Aug; 270():495-496. PubMed ID: 39079354
    [No Abstract]   [Full Text] [Related]  

  • 2. Corrigendum to "Therapeutic Effectiveness and Tolerability of Aripiprazole as Initial Choice of Treatment in First Episode Psychosis in an Early Intervention Service: A One-Year Outcome Study" [Schizophr. Res. 147, 120-125].
    Malla A; Mustafa S; Rho A; Abadi S; Lepage M; Joober R
    Schizophr Res; 2018 Mar; 193():490. PubMed ID: 29550056
    [No Abstract]   [Full Text] [Related]  

  • 3. Corrigendum to "abnormal white matter integrity in antipsychotic-naïve first-episode psychosis patients assessed by a DTI principal component analysis" [Schizophr. Res. 162 (1-3) (march 2015) 14-21].
    Alvarado-Alanis P; León-Ortiz P; Reyes-Madrigal F; Favila R; Rodríguez-Mayoral O; Nicolini H; Azcárraga M; Graff-Guerrero A; Rowland LM; de la Fuente-Sandoval C
    Schizophr Res; 2016 Oct; 176(2-3):582. PubMed ID: 27264503
    [No Abstract]   [Full Text] [Related]  

  • 4. Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study.
    Millgate E; Smart SE; Pardiñas AF; Kravariti E; Ajnakina O; Kępińska AP; Andreassen OA; Barnes TRE; Berardi D; Crespo-Facorro B; D'Andrea G; Demjaha A; Di Forti M; Doody GA; Kassoumeri L; Ferchiou A; Guidi L; Joyce EM; Lastrina O; Melle I; Pignon B; Richard JR; Simonsen C; Szöke A; Tarricone I; Tortelli A; Vázquez-Bourgon J; Murray RM; Walters JTR; MacCabe JH;
    Schizophr Res; 2023 May; 255():173-181. PubMed ID: 37001392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corrigendum to "Neuroanatomical correlates of perceptual aberrations in psychosis" [Schizophr. Res. 179 (2017) 125-131].
    Brosey EA; Woodward ND
    Schizophr Res; 2018 Jul; 197():624. PubMed ID: 29699896
    [No Abstract]   [Full Text] [Related]  

  • 6. Corrigendum to "self-reported cannabis use is inconsistent with the results from drug-screening in youth at ultra high-risk for psychosis in Colorado" [Schizophr. Res. 157 (0) (August 2014) 317-318].
    Carol EE; Mittal VA
    Schizophr Res; 2018 Feb; 192():494. PubMed ID: 28476338
    [No Abstract]   [Full Text] [Related]  

  • 7. Corrigendum to "resilience in schizophrenia: A comparative study between a remote island and an urban area in Japan" [Schizophr. Res. Volume 171, Issues 1-3, March 2016, Pages 92-96].
    Yoshida K; Suzuki T; Imasaka Y; Kubo KI; Mizuno Y; Saruta J; Tsukinoki K; Mimura M; Uchida H
    Schizophr Res; 2016 Oct; 176(2-3):580. PubMed ID: 27539074
    [No Abstract]   [Full Text] [Related]  

  • 8. Corrigendum to "Cognitive-behavioral social skills training for patients with late-life schizophrenia and the moderating effect of executive dysfunction" [Schizophr. Res. 239 (2022) 160-167].
    Rajji TK; Mamo DC; Holden J; Granholm E; Mulsant BH
    Schizophr Res; 2023 Jun; 256():136. PubMed ID: 35787806
    [No Abstract]   [Full Text] [Related]  

  • 9. Corrigendum to "Long-term course of negative symptom subdomains and relationship with outcome in patients with a psychotic disorder" [Schizophr. Res. 193 (2018) 173-181].
    Stiekema APM; Islam MA; Liemburg EJ; Castelein S; van den Heuvel ER; van Weeghel J; Aleman A; Bruggeman R; van der Meer L; ; Alizadeh BZ; Bartels-Velthuis AA; van Beveren NJ; Bruggeman R; Cahn W; de Haan L; Delespaul P; Meijer CJ; Myin-Germeys I; Kahn RS; Schirmbeck F; Simons CJP; van Haren NEM; van Os J; van Winkel R
    Schizophr Res; 2019 Feb; 204():462-463. PubMed ID: 30314649
    [No Abstract]   [Full Text] [Related]  

  • 10. Corrigendum to "The danger of averages in the context of heterogeneity: Response to the letter to the editor of SCZ RES - role of ECT in patients with CRS - Markota et al., 2024" [Schizophr. Res. 269 (2024): 120-122].
    Elkis H
    Schizophr Res; 2024 Sep; ():. PubMed ID: 39232890
    [No Abstract]   [Full Text] [Related]  

  • 11. Psychological intervention, antipsychotic medication or a combined treatment for adolescents with a first episode of psychosis: the MAPS feasibility three-arm RCT.
    Morrison AP; Pyle M; Byrne R; Broome M; Freeman D; Johns L; James A; Husain N; Whale R; MacLennan G; Norrie J; Hudson J; Peters S; Davies L; Bowe S; Smith J; Shiers D; Joyce E; Jones W; Hollis C; Maughan D
    Health Technol Assess; 2021 Jan; 25(4):1-124. PubMed ID: 33496261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corrigendum to "Phenotype continuum between autism and schizophrenia: Evidence from the Movie for the Assessment of the social cognition (MASC)" [Schizophr. Res. 185 (2017) 161-166].
    Martinez G; Alexandre C; Mam-Lam-Fook C; Bendjemaa N; Gaillard R; Garel P; Dziobek I; Amado I; Krebs MO
    Schizophr Res; 2018 Mar; 193():489. PubMed ID: 29550055
    [No Abstract]   [Full Text] [Related]  

  • 13. Corrigendum to cytochrome P450 genotypes are not associated with refractoriness to antipsychotic treatment [Schizophr. Res. 168 (2015) 587-588].
    van de Bilt MT; Prado CM; Ojopi EPB; de Sousa RT; Loch AA; Zanetti MV; Talib LL; Gattaz WF
    Schizophr Res; 2016 Jul; 174(1-3):204. PubMed ID: 27066861
    [No Abstract]   [Full Text] [Related]  

  • 14. Corrigendum to "Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study" [Schizophr. Res. 239 (2022) 83-91].
    Filts Y; Litman RE; Martínez J; Anta L; Naber D; Correll CU
    Schizophr Res; 2022 Aug; 246():258-259. PubMed ID: 35853294
    [No Abstract]   [Full Text] [Related]  

  • 15. Neuropsychological status of subjects at high risk for a first episode of psychosis.
    Hawkins KA; Addington J; Keefe RS; Christensen B; Perkins DO; Zipurksy R; Woods SW; Miller TJ; Marquez E; Breier A; McGlashan TH
    Schizophr Res; 2004 Apr; 67(2-3):115-22. PubMed ID: 14984870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corrigendum to "Revisiting the latent structure of negative symptoms in schizophrenia: Evidence from two second-generation clinical assessments" [Schizophr. Res. 248 (2022) 131-139].
    Li SB; Liu C; Zhang JB; Wang LL; Hu HX; Chu MY; Wang Y; Lv QY; Lui SSY; Cheung EFC; Yi ZH; Chan RCK
    Schizophr Res; 2023 Feb; 252():206-207. PubMed ID: 36657365
    [No Abstract]   [Full Text] [Related]  

  • 17. Corrigendum to "Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial" [Schizophr. Res. 176 (2016) 264-271].
    Durgam S; Earley W; Li R; Li D; Lu K; Laszlovszky I; Wolfgang Fleischhacker W; Nasrallah HA
    Schizophr Res; 2018 Feb; 192():493. PubMed ID: 28427929
    [No Abstract]   [Full Text] [Related]  

  • 18. Corrigendum to "Self and time in individuals with schizophrenia: A motor component?" [Schizophr. Res. 272 (2024) 12-19 (October)].
    Foerster FR; Joos E; Martin B; Coull JT; Giersch A
    Schizophr Res; 2024 Oct; 274():269. PubMed ID: 39395269
    [No Abstract]   [Full Text] [Related]  

  • 19. Corrigendum to "Long-term hospitalizations for schizophrenia in the Czech Republic 1998-2012" (Schizophr. Res. vol. 175, issues 1-3, August 2016, pages 180-185).
    PetrWinkler ; Mladá K; Krupchanka D; Agius M; Ray MK; Höschl C
    Schizophr Res; 2016 Oct; 176(2-3):581. PubMed ID: 27476650
    [No Abstract]   [Full Text] [Related]  

  • 20. WITHDRAWN: Corrigendum to "Dose and safety concerns of clozapine: Worldwide package inserts need revisions" [Schizophr. Res. 08619].
    de Leon J; Ruan CJ; Schoretsanitis G; Kane JM
    Schizophr Res; 2020 Feb; ():. PubMed ID: 32019683
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.